RLAY logo

Relay Therapeutics Inc. (RLAY)

$16.47

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on RLAY

Market cap

$3.64B

EPS

-1.5

P/E ratio

--

Price to sales

378.58

Dividend yield

--

Beta

1.752972

Price on RLAY

Previous close

$17.27

Today's open

$17.20

Day's range

$16.39 - $17.42

52 week range

$6.17 - $21.27

Profile about RLAY

CEO

Sanjiv K. Patel

Employees

202

Headquarters

Cambridge, MA

Exchange

NASDAQ Global Market

Shares outstanding

220959470

Issue type

Common Stock

RLAY industries and sectors

Healthcare

Biotechnology & Life Sciences

News on RLAY

Relay Therapeutics, Inc. (RLAY) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

Relay Therapeutics, Inc. ( RLAY ) 3rd Annual Guggenheim Healthcare Innovation Conference November 10, 2026 4:30 PM EST Company Participants Sanjiv Patel - CEO, President & Director Peter Rahmer - Chief Corporate Development Officer Donald Bergstrom - President of Research & Development Conference Call Participants Debjit Chattopadhyay - Guggenheim Securities, LLC Presentation Debjit Chattopadhyay Guggenheim Securities, LLC All right. Good afternoon.

news source

Seeking Alpha • Nov 11, 2026

news preview

Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates

Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies to be featured in oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition; Relay to hold conference call to discuss data and provide regulatory update Shannon Campbell to lead commercial preparations for zovegalisib in breast cancer and vascular anomalies Announced second vascular anomalies program for mutant-selective TIE2 inhibitor Approximately $849 million in cash, cash equivalents and investments at end of Q3 2026  CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today reported third quarter 2026 financial results and corporate updates.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November

CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in three upcoming fireside chats in November:

news source

GlobeNewsWire • Nov 2, 2026

news preview

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report third quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 4, 2026.

news source

GlobeNewsWire • Oct 28, 2026

news preview

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter

Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.

news source

CNBC Television • Oct 6, 2026

news preview

Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

news source

Seeking Alpha • Sep 16, 2026

news preview

Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript

news source

Seeking Alpha • Sep 10, 2026

news preview

Relay Therapeutics CFO Sells 17,717 Shares for $350,000

The sale had an approximate value of nearly $350,000. The transaction reduced the executive's direct equity position by 11%.

news source

The Motley Fool • Sep 2, 2026

news preview

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:

news source

GlobeNewsWire • Sep 1, 2026

news preview

This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion

After skyrocketing 1,027% off a low, Relay Therapeutics taps AI and machine learning to fuel more gains.

news source

Investors Business Daily • Aug 20, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Relay Therapeutics Inc.

Open an M1 investment account to buy and sell Relay Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in RLAY on M1